RIPK1 and pulmonary emphysema: GSK’547 is a RIPK1 inhibitor that significantly reduces elastase-induced emphysema and lung function decline, diminishes CS-induced peri-bronchial inflammatory cell infiltration, airway collagen deposition, and emphysema-like changes [52].